Examining the expression pattern of immune checkpoint genes in glioblastoma cell line treated with Toxoplasma gondii lysate

Abstract

Glioblastoma (GBM) is the most common and aggressive primary brain tumor and is associated with a very poor prognosis and a median survival time of only 8–12 months 1–4, and the 5-year survival rate is still less than 10%. The current standard of care (SOC) for GBM is maximal surgical resection followed by radiotherapy and temozolomide chemotherapy, and no other drugs have been added to SOC to date. In randomized clinical trials, targeted agents and antiangiogenic therapy failed to demonstrate a survival benefit. Therefore, new therapeutic strategies are urgently needed. Material and Methods: The cell line is cultured in RPMI1640 medium and after the cells reach logarithmic growth, two groups with/without T. gondii lysate treated will be considered. After 24 hours, the cells will be collected for mRNA extraction, and after cDNA synthesis. The expression of the genes examined by RT-PCR. Results: The qRT-PCR test showed changes in the expression of CD80, and miR-155 in U373 cells under treatment with T. gondii lysate, which showed a decrease in the expression of CD80, and miR-155.